Compare Remitly Global Inc (RELY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Remitly Global Inc trades at $23.48 (market cap $5.03B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Remitly Global Inc is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| RELY | SYRE | |
|---|---|---|
Market Cap | $5.03B | $7.52B |
Volume | 2,682,448 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $26.92 | $108.92 |
52-Week Low | $12.20 | $22.18 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $4.39B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $23.49, showing modest daily movement with strong technical momentum. The company demonstrates accelerating revenue growth, reaching $1.64 billion in 2025 with improving profitability margins. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.93 significantly exceeding the $0.12 forecast. Analyst sentiment remains overwhelmingly positive with 92% buy ratings and a $30.50 consensus price target, representing 30% upside potential from current levels.
The outlook remains bullish given strong fundamentals and growth trajectory, though the stock faces risks from competitive pressures and potential market volatility. RELY's transition to profitability and expanding customer base to over 10 million active users supports continued upside, while elevated valuation multiples require sustained execution to justify current levels.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
